Lucknow Speciality Pharma
Palbociclib Capsules was reviewed and approved under the Food and Drug Administration’s (FDA) accelerated Priority Review and Breakthrough Therapy designation programs on February 3, 2015 as a treatment (in combination with letrozole) for patients with estrogen receptor positive (ER+) advanced breast cancer.

Palbociclib Capsules
- Brand Name – Palbace
- Innovator Brand Name – Ibrance
- API – Palbociclib
- Packaging – 21 Capsules
- Strength – 75 mg, 100 mg & 125 mg
- Manufacturer Name – Pfizer Ltd.
What is palbociclib used for?
Palbociclib Capsules is a kinase inhibitor indicated for the treatment of HR-Positive, HER2-Negative advanced as well as metastatic breast cancer in the combination with:
- An aromatase inhibitor:
As an initial endocrine-based therapy in postmenopausal women.
About Us
Lucknow Speciality Pharma is dedicated to delivering life-changing healthcare solutions. As a trusted wholesale supplier of specialized medicines, we cater to critical care areas such as oncology, nephrology, and rare diseases. Our patient-centric approach also includes personalized catering services, ensuring that patients receive the care, support, and nutrition they need to thrive. We also extend our services globally, welcoming international patients and buyers who seek our expertise and high-quality products.
Lucknow Speciality Pharma is a registered Pharmaceutical Firm in Lucknow, India. Registered under GST Act. Registration Number : 09AAOPG3102HIZY. It provide assistance and connectivity with drug pharmacies or distributors for access to genuine medicines at competitive prices.
Get Access To Palbociclib Capsules 75 mg
Enter Buying Requirements Details
For precise quotations, kindly ensure your requirements include the product name, order quantity, intended usage, and any special requests you may have.
Branch Offices in India : Lucknow | Agra | Varanasi | Gorakhpur | Kanpur | Indore | Patna | Kolkata | Nepal
FAQs – Medicine Questions
Is Palbociclib a targeted therapy?
Palbociclib is a targeted therapy; it targets cyclin-dependent kinases.
Is Palbociclib FDA approved?
Yes.
What are the ingredients of the medicine Palbociclib?
The active ingredient is Palbociclib, and the inactive ingredients are microcrystalline cellulose, colloidal silicon dioxide, crospovidone, magnesium stearate, succinic acid, HPMC 2910/hypromellose, titanium dioxide, triacetin, and FD&C Blue #2/Indigo Carmine Aluminum Lake.
Where can I buy Palbociclib Capsules?
You can buy Palbociclib Capsules from any authorized whole-seller after getting a prescription from a qualified doctor. It is always better to check the credential of the whole-seller/supplier/exporter before buying the product.
The buyer should check the existing law in their home country before importing the product.
What is the procedure to buy Palbociclib Capsules?
Patients can simply fill the order form or can send mail at info@lucknowpharma.com. Patients can also send WhatsApp messages to +91-9555306364 We will reply ASAP with the details of the Palbociclib Capsule price as well as procurement procedure.
Note:- The order will be confirmed only after the receipt of the Valid prescription of the Clinician.
What kind of drug is Palbociclib?
Palbociclib is a kinase inhibitor drug that targets cyclin-dependent kinase.
NEWS / UPDATES
- Pfizer Limited, Electronic medicines compendium (emc), [Revised on June 2021] [ Accessed on 2nd Dec 2021], https://www.medicines.org.uk/emc/files/pil.4449.pdf
- Pfizer Labs, US Food and Drug Administration, [Revised on March 2017] [ Accessed on 2nd Dec 2021], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207103s004lbl.pdf
- Neha S Mangini et al; Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer; The Annals of Pharmacotherapy; Published on Nov 2015; Accessed on 03/12/2021; https://pubmed.ncbi.nlm.nih.gov/26324355/